Terms: = Liver cancer AND SMAD3, JV15-2, 4088, ENSG00000166949, P84022, Smad3, MADH3, HsT17436, Smad 3, DKFZp686J10186, HSPC193, DKFZP586N0721, MGC60396 AND Treatment
62 results:
1. TGF-β1/smad3-driven GLI2 isoform expression contributes to aggressive phenotypes of hepatocellular carcinoma.
Ding J; Yang YY; Li PT; Ma Y; Zhang L; Zhou Y; Jin C; Li HY; Zhu YF; Liu XP; Liu ZJ; Jia HL; Liu PG; Wu J
Cancer Lett; 2024 Apr; 588():216768. PubMed ID: 38453045
[TBL] [Abstract] [Full Text] [Related]
2. An NFATc1/smad3/cJUN Complex Restricted to smad4-Deficient Pancreatic cancer Guides Rational Therapies.
Hasselluhn MC; Schlösser D; Versemann L; Schmidt GE; Ulisse M; Oschwald J; Zhang Z; Hamdan F; Xiao H; Kopp W; Spitalieri J; Kellner C; Schneider C; Reutlinger K; Nagarajan S; Steuber B; Sastra SA; Palermo CF; Appelhans J; Bohnenberger H; Todorovic J; Kostyuchek I; Ströbel P; Bockelmann A; König A; Ammer-Herrmenau C; Schmidleitner L; Kaulfuß S; Wollnik B; Hahn SA; Neesse A; Singh SK; Bastians H; Reichert M; Sax U; Olive KP; Johnsen SA; Schneider G; Ellenrieder V; Hessmann E
Gastroenterology; 2024 Feb; 166(2):298-312.e14. PubMed ID: 37913894
[TBL] [Abstract] [Full Text] [Related]
3. AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/smad3 pathway.
Deng L; Bao W; Zhang B; Zhang S; Chen Z; Zhu X; He B; Wu L; Chen X; Deng T; Chen B; Yu Z; Wang Y; Chen G
Cell Death Dis; 2023 Sep; 14(9):590. PubMed ID: 37669935
[TBL] [Abstract] [Full Text] [Related]
4. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art.
Lu G; Wang X; Cheng M; Wang S; Ma K
Biomed Pharmacother; 2023 Sep; 165():115132. PubMed ID: 37423169
[TBL] [Abstract] [Full Text] [Related]
5. Activin A/ACVR2A axis inhibits epithelial-to-mesenchymal transition in colon cancer by activating smad2.
Zhang H; Ruan Q; Chen C; Yu H; Guan S; Hu D; Yang C; Lin R; Zhuo C
Mol Carcinog; 2023 Oct; 62(10):1585-1598. PubMed ID: 37378449
[TBL] [Abstract] [Full Text] [Related]
6. Apoptotic and Anti-metastatic Effects of Atractylodes lancea (Thunb.) DC. in a Hamster Model of Cholangiocarcinoma.
Sonsomnuek P; Tarasuk M; Plengsuriyakarn T; Boonprasert K; Na-Bangchang K
Asian Pac J Cancer Prev; 2022 Sep; 23(9):3093-3101. PubMed ID: 36172672
[TBL] [Abstract] [Full Text] [Related]
7. TGF-β1/smad3 upregulates UCA1 to promote liver fibrosis through DKK1 and miR18a.
Yang Z; Zhang H; Yin M; Cheng Z; Jiang P; Feng M; Liu Z; Liao B
J Mol Med (Berl); 2022 Oct; 100(10):1465-1478. PubMed ID: 36001113
[TBL] [Abstract] [Full Text] [Related]
8. RNA
Tan B; Zhou K; Liu W; Prince E; Qing Y; Li Y; Han L; Qin X; Su R; Pokharel SP; Yang L; Zhao Z; Shen C; Li W; Chen Z; Zhang Z; Deng X; Small A; Wang K; Leung K; Chen CW; Shen B; Chen J
Theranostics; 2022; 12(13):5727-5743. PubMed ID: 35966596
[TBL] [Abstract] [Full Text] [Related]
9. The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways.
Zhao M; Wang Y; Zhang Y; Li X; Mi J; Wang Q; Geng Z; Zuo L; Song X; Ge S; Zhang Z; Tang M; Li H; Wang Z; Jiang C; Su F
BMC Gastroenterol; 2022 Aug; 22(1):378. PubMed ID: 35941537
[TBL] [Abstract] [Full Text] [Related]
10. Synthesis and structure-activity relationship study of a potent MHO7 analogue as potential anti-triple negative breast cancer agent.
Liang JJ; Yu WL; Yang L; Qin KM; Yin YP; Li D; Ni YH; Yan JJ; Zhong YX; Deng ZX; Hong K
Eur J Med Chem; 2022 Jun; 236():114313. PubMed ID: 35390712
[TBL] [Abstract] [Full Text] [Related]
11. PTBP3 mediates TGF-β-induced EMT and metastasis of lung adenocarcinoma.
Dong C; Wu K; Gu S; Wang W; Xie S; Zhou Y
Cell Cycle; 2022 Jul; 21(13):1406-1421. PubMed ID: 35323096
[TBL] [Abstract] [Full Text] [Related]
12. Astragaloside IV suppresses migration and invasion of TGF-β
Li L; Wang Q; He Y; Sun L; Yang Y; Pang X
Naunyn Schmiedebergs Arch Pharmacol; 2022 Apr; 395(4):397-405. PubMed ID: 35092472
[TBL] [Abstract] [Full Text] [Related]
13. Berberine Suppresses EMT in liver and Gastric Carcinoma Cells through Combination with TGF
Du H; Gu J; Peng Q; Wang X; Liu L; Shu X; He Q; Tan Y
Oxid Med Cell Longev; 2021; 2021():2337818. PubMed ID: 34712379
[TBL] [Abstract] [Full Text] [Related]
14. Rebalancing TGF-β/smad7 signaling via Compound kushen injection in hepatic stellate cells protects against liver fibrosis and hepatocarcinogenesis.
Yang Y; Sun M; Li W; Liu C; Jiang Z; Gu P; Li J; Wang W; You R; Ba Q; Li X; Wang H
Clin Transl Med; 2021 Jul; 11(7):e410. PubMed ID: 34323416
[TBL] [Abstract] [Full Text] [Related]
15. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating psmad3C/3L and Nrf2/HO-1 pathways.
Zhang C; Li L; Hou S; Shi Z; Xu W; Wang Q; He Y; Gong Y; Fang Z; Yang Y
J Ethnopharmacol; 2021 Oct; 279():114350. PubMed ID: 34157326
[TBL] [Abstract] [Full Text] [Related]
16. Doxorubicin hydrochloride enhanced antitumour effect of CEA-regulated oncolytic virotherapy in live cancer cells and a mouse model.
Xiao B; Ying C; Chen Y; Huang F; Wang B; Fang H; Guo W; Liu T; Zhou X; Huang B; Liu X; Wang Y
J Cell Mol Med; 2020 Nov; 24(22):13431-13439. PubMed ID: 33251723
[TBL] [Abstract] [Full Text] [Related]
17. Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis.
Ren J; Wang Y; Ware T; Iaria J; Ten Dijke P; Zhu HJ
Cancer Lett; 2020 Nov; 493():41-54. PubMed ID: 32768522
[TBL] [Abstract] [Full Text] [Related]
18. TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells.
Kim DH; Kim WD; Kim SK; Moon DH; Lee SJ
Cell Death Dis; 2020 May; 11(5):406. PubMed ID: 32471991
[TBL] [Abstract] [Full Text] [Related]
19. Statin inhibits large hepatitis delta antigen-smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion.
Liang YJ; Sun CP; Hsu YC; Chen YW; Wang IA; Su CW; Tao MH; Wu JC
J Biomed Sci; 2020 May; 27(1):65. PubMed ID: 32434501
[TBL] [Abstract] [Full Text] [Related]
20. Shikonin suppresses progression and epithelial-mesenchymal transition in hepatocellular carcinoma (HCC) cells by modulating miR-106b/smad7/TGF-β signaling pathway.
Li X; Zeng X
Cell Biol Int; 2020 Feb; 44(2):467-476. PubMed ID: 31617643
[TBL] [Abstract] [Full Text] [Related]
[Next]
